{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:58:17Z","timestamp":1767193097375,"version":"3.48.0"},"reference-count":37,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NFSG230327876072024-02-13 SABG"],"award-info":[{"award-number":["NFSG230327876072024-02-13 SABG"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Many patients with tuberculosis (TB) suffer from a huge economic burden, even though TB services are often provided free of charge at the point of care. Costs can create significant barriers, hindering patients\u2019 access to TB treatment. These costs include direct medical costs (such as consultation fees), direct non-medical costs (such as transportation costs) and indirect costs (such as wages foregone). This systematic review aims to synthesise the best available evidence on economic evaluations of patient-cost studies on self-administered treatment (SAT) for drug-sensitive TB compared with facility-based directly observed treatment, short-course (FB DOTS), globally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We will conduct a systematic review following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and search PubMed, Academic Search Complete, Scopus, CINAHL Plus (EBSCO) and Google Scholar for articles published up to 2025, without date restrictions. Eligible studies must be full or partial (cost analyses without effectiveness data) economic evaluations conducted globally, comparing SAT to FB DOTS regarding TB patient costs. Grey literature will be included. Exclusion criteria include studies not reporting patient costs between SAT and FB DOTS, and non-economic evaluations (non-original research). Two independent reviewers will conduct the screening, data extraction and quality assessment. A quality assessment will be performed using the Consolidated Health Economic Evaluation Reporting Standards statement, the Consensus on Health Economic Criteria checklist and the ROBINS-I tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval is not required for this systematic review because it does not use individual patient data. Instead, we will use publicly available economic evaluation research studies. Findings will be presented at international and national conferences and published in open-access, peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024591221.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-099124","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:30:24Z","timestamp":1755059424000},"page":"e099124","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-cost studies on self-administered treatment (SAT) for drug-sensitive tuberculosis compared to facility-based directly observed treatment, short-course (DOTS): a protocol for a systematic review"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8263-320X","authenticated-orcid":false,"given":"Yonela Faith","family":"Ndlangalavu","sequence":"first","affiliation":[{"name":"Economics, University of the Western Cape, Cape Town, Western Cape, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-6561","authenticated-orcid":false,"given":"Carmen Sue","family":"Christian","sequence":"additional","affiliation":[{"name":"Economics, University of the Western Cape, Cape Town, Western Cape, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2025123106461459000_15.8.e099124.1","unstructured":"WHO . Global tuberculosis report 2021. World Health Organization; 2021. Available: https:\/\/iris.who.int\/handle\/10665\/346387 [accessed 25 Sep 2023]"},{"key":"2025123106461459000_15.8.e099124.2","unstructured":"WHO . Global tuberculosis report 2022. 2022. Available: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2022 [accessed 25 Sep 2023]"},{"key":"2025123106461459000_15.8.e099124.3","unstructured":"WHO . Global tuberculosis report 2024. 2024. Available: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024 [accessed 30 Oct 2024]"},{"key":"2025123106461459000_15.8.e099124.4","unstructured":"Bill & Melinda Gates Foundation . Bill & Melinda Gates Foundation; Tuberculosis - Eradication & Prevention | Gates Foundation, 2024. Available: http:\/\/www.gatesfoundation.org\/our-work\/programs\/global-health\/tuberculosis [Accessed 16 Aug 2024]."},{"key":"2025123106461459000_15.8.e099124.5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014014","article-title":"Patients\u2019 costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil","volume":"5","author":"Steffen","year":"2010","journal-title":"PLoS ONE"},{"key":"2025123106461459000_15.8.e099124.6","unstructured":"Ahlburg DA , Initiative ST . The economic impacts of tuberculosis. In: Amsterdam N , ed. Ministerial Conference on Tuberculosis and Sustainable Development (2000). 2000. Available: https:\/\/iris.who.int\/handle\/10665\/66238 [accessed 16 Jul 2024]."},{"key":"2025123106461459000_15.8.e099124.7","unstructured":"Stop TB Partnership . Stop TB Partnership; The Global Plan to Stop TB 2016 - 2020, 2015. Available: http:\/\/www.stoptb.org\/global\/plan\/plan2\/ [Accessed 5 May 2024]."},{"key":"2025123106461459000_15.8.e099124.8","unstructured":"WHO . Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update, 2014. Available: https:\/\/www.who.int\/publications\/i\/item\/9789241550000 [Accessed 17 Jul 2014]."},{"key":"2025123106461459000_15.8.e099124.9","unstructured":"WHO . operational handbook on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment, 2022. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240050761 [Accessed 17 Jul 2024]."},{"key":"2025123106461459000_15.8.e099124.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-10267-0","article-title":"Socio-economic drivers of drug-resistant tuberculosis in Africa: a scoping review","volume":"21","author":"Cannon","year":"2021","journal-title":"BMC Public Health"},{"key":"2025123106461459000_15.8.e099124.11","doi-asserted-by":"crossref","DOI":"10.1186\/s40249-021-00879-4","article-title":"Determinants of household catastrophic costs for drug sensitive tuberculosis patients in Kenya","volume":"10","author":"Kirubi","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"2025123106461459000_15.8.e099124.12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.rppnen.2017.10.009","article-title":"New drugs and perspectives for new anti-tuberculosis regimens \u2606","volume":"24","author":"Tiberi","year":"2018","journal-title":"Pulmonology"},{"key":"2025123106461459000_15.8.e099124.13","unstructured":"WHO . Global Tuberculosis Report. Geneva, Switzerland: World Health Organization, 2018."},{"key":"2025123106461459000_15.8.e099124.14","unstructured":"Dholakia R , Almeida J , Programme WGT . The potential economic benefits of the DOTS strategy against TB in India, 1997. Available: https:\/\/iris.who.int\/handle\/10665\/63467 [Accessed 16 Jul 2024]."},{"key":"2025123106461459000_15.8.e099124.15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1164\/ajrccm.154.4.8887600","article-title":"Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis","volume":"154","author":"Moore","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2025123106461459000_15.8.e099124.16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/bmj.315.7120.1407","article-title":"Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa","volume":"315","author":"Floyd","year":"1997","journal-title":"BMJ"},{"key":"2025123106461459000_15.8.e099124.17","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1136\/thx.54.2008.S42","article-title":"Directly observed therapy (DOT) for tuberculosis: why, when, how and if?","volume":"54 Suppl 2","author":"Ormerod","year":"1999","journal-title":"Thorax"},{"key":"2025123106461459000_15.8.e099124.18","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czi047"},{"key":"2025123106461459000_15.8.e099124.19","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/17.2.178"},{"key":"2025123106461459000_15.8.e099124.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108186","article-title":"Self-administered tuberculosis treatment outcomes in a tribal population on the indo-myanmar border, Nagaland, India","volume":"9","author":"Das","year":"2014","journal-title":"PLoS ONE"},{"key":"2025123106461459000_15.8.e099124.21","doi-asserted-by":"crossref","unstructured":"Cobucci RNO . A Meta-Analysis of Directly Observed Treatment vs. Self- Administered Therapy Outcomes in pulmonary Tuberculosis Patients, 2017. Available: https:\/\/clinmedjournals.org\/articles\/jide\/journal-of-infectious-diseases-and-epidemiology-jide-3-027.php [Accessed 16 Jul 2024].","DOI":"10.23937\/2474-3658\/1510027"},{"key":"2025123106461459000_15.8.e099124.22","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0867"},{"key":"2025123106461459000_15.8.e099124.23","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-3-6"},{"key":"2025123106461459000_15.8.e099124.24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.socscimed.2015.01.046","article-title":"The economic burden of TB diagnosis and treatment in South Africa","volume":"130","author":"Foster","year":"2015","journal-title":"Social Science & Medicine"},{"key":"2025123106461459000_15.8.e099124.25","unstructured":"WHO . Tuberculosis patient cost surveys: a handbook, 2017. Available: https:\/\/www.who.int\/publications\/i\/item\/9789241513524 [Accessed 11 Jul 2024]."},{"key":"2025123106461459000_15.8.e099124.26","unstructured":"WHO . Global tuberculosis report, 2023. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240083851 [Accessed 3 Jul 2024]."},{"key":"2025123106461459000_15.8.e099124.27","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-12-980","article-title":"Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa--a systematic review","volume":"12","author":"Barter","year":"2012","journal-title":"BMC Public Health"},{"key":"2025123106461459000_15.8.e099124.28","unstructured":"OANDA . Understanding the costs of tuberculosis treatment. 2020."},{"key":"2025123106461459000_15.8.e099124.29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s41669-017-0057-9","article-title":"Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand","volume":"2","author":"Tanvejsilp","year":"2018","journal-title":"Pharmacoecon Open"},{"key":"2025123106461459000_15.8.e099124.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025123106461459000_15.8.e099124.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"2025123106461459000_15.8.e099124.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"2025123106461459000_15.8.e099124.33","unstructured":"Mamabolo M . Subject Guides: Covidence: Home, 2022. Available: https:\/\/libguides.uwc.ac.za\/c.php?g=1244990&p=9109409 [Accessed 29 Jun 2024]."},{"key":"2025123106461459000_15.8.e099124.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025123106461459000_15.8.e099124.35","doi-asserted-by":"publisher","DOI":"10.1017\/s0266462305050324"},{"key":"2025123106461459000_15.8.e099124.36","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2393-14-243","article-title":"Cost-effectiveness of strategies to improve the utilization and provision of maternal and newborn health care in low-income and lower-middle-income countries: a systematic review","volume":"14","author":"Mangham-Jefferies","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"2025123106461459000_15.8.e099124.37","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/epi.13655","article-title":"A systematic review of economic evaluations of treatments for patients with epilepsy","volume":"58","author":"Wijnen","year":"2017","journal-title":"Epilepsia"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-099124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:47:20Z","timestamp":1767192440000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-099124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,12]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2025-099124"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-099124","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}